Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL

NCT03161223 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT03161223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03161223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Lead sponsor
University of Virginia
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 30, 2018
Completion date
February 28, 2023
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, t-cell